Non-NGS Predictive Cancer Diagnostics Market

Future Market Insights

Non-NGS Predictive Cancer Diagnostics Market

Key Insight

The global Non-NGS predictive cancer diagnostics market is projected to grow from USD 1,200 million in 2025 to USD 2,713.2 million by 2035, at a CAGR of 8.5%. PCR-based companion diagnostics will dominate with a 30% share in 2025, while therapy selection/companion Dx applications will capture 58% of the market.

December 05, 2025

Anurag Sharma

250 Pages

Cite this Report

Non-NGS Predictive Cancer Diagnostics Market

https://www.futuremarketinsights.com/reports/non-ngs-predictive-cancer-diagnostics-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Abbott Laboratories
Bio-Rad
Hoffmann-La Roche
Siemens
Thermo Fisher

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Non-NGS Predictive Cancer Diagnostics Market

Key Players

Similar Industry Reports